Abstract
Summary
LPI (LP Information)' newest research report, the “Batten Disease Drug Pipeline Industry Forecast” looks at past sales and reviews total world Batten Disease Drug Pipeline sales in 2022, providing a comprehensive analysis by region and market sector of projected Batten Disease Drug Pipeline sales for 2023 through 2029. With Batten Disease Drug Pipeline sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Batten Disease Drug Pipeline industry.
This Insight Report provides a comprehensive analysis of the global Batten Disease Drug Pipeline landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Batten Disease Drug Pipeline portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Batten Disease Drug Pipeline market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Batten Disease Drug Pipeline and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Batten Disease Drug Pipeline.
The global Batten Disease Drug Pipeline market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Batten Disease Drug Pipeline is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Batten Disease Drug Pipeline is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Batten Disease Drug Pipeline is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Batten Disease Drug Pipeline players cover Abeona Therapeutics Inc, Amicus Therapeutics, Blue Turtle Bio Technologies Inc, Circumvent Pharmaceuticals Inc, Collaborations Pharmaceuticals Inc, Exicure Inc, Polaryx Therapeutics Inc, RegenxBio Inc and Retrotope Inc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Batten Disease Drug Pipeline market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Gene Drugs
Stem Cell Drugs
Segmentation by application
Hospital and Clinics
Specialty Centers
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abeona Therapeutics Inc
Amicus Therapeutics
Blue Turtle Bio Technologies Inc
Circumvent Pharmaceuticals Inc
Collaborations Pharmaceuticals Inc
Exicure Inc
Polaryx Therapeutics Inc
RegenxBio Inc
Retrotope Inc
This Insight Report provides a comprehensive analysis of the global Batten Disease Drug Pipeline landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Batten Disease Drug Pipeline portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Batten Disease Drug Pipeline market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Batten Disease Drug Pipeline and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Batten Disease Drug Pipeline.
The global Batten Disease Drug Pipeline market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Batten Disease Drug Pipeline is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Batten Disease Drug Pipeline is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Batten Disease Drug Pipeline is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Batten Disease Drug Pipeline players cover Abeona Therapeutics Inc, Amicus Therapeutics, Blue Turtle Bio Technologies Inc, Circumvent Pharmaceuticals Inc, Collaborations Pharmaceuticals Inc, Exicure Inc, Polaryx Therapeutics Inc, RegenxBio Inc and Retrotope Inc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Batten Disease Drug Pipeline market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Gene Drugs
Stem Cell Drugs
Segmentation by application
Hospital and Clinics
Specialty Centers
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abeona Therapeutics Inc
Amicus Therapeutics
Blue Turtle Bio Technologies Inc
Circumvent Pharmaceuticals Inc
Collaborations Pharmaceuticals Inc
Exicure Inc
Polaryx Therapeutics Inc
RegenxBio Inc
Retrotope Inc
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Batten Disease Drug Pipeline Market Size 2018-2029
2.1.2 Batten Disease Drug Pipeline Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Batten Disease Drug Pipeline Segment by Type
2.2.1 Gene Drugs
2.2.2 Stem Cell Drugs
2.3 Batten Disease Drug Pipeline Market Size by Type
2.3.1 Batten Disease Drug Pipeline Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Batten Disease Drug Pipeline Market Size Market Share by Type (2018-2023)
2.4 Batten Disease Drug Pipeline Segment by Application
2.4.1 Hospital and Clinics
2.4.2 Specialty Centers
2.5 Batten Disease Drug Pipeline Market Size by Application
2.5.1 Batten Disease Drug Pipeline Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Batten Disease Drug Pipeline Market Size Market Share by Application (2018-2023)
3 Batten Disease Drug Pipeline Market Size by Player
3.1 Batten Disease Drug Pipeline Market Size Market Share by Players
3.1.1 Global Batten Disease Drug Pipeline Revenue by Players (2018-2023)
3.1.2 Global Batten Disease Drug Pipeline Revenue Market Share by Players (2018-2023)
3.2 Global Batten Disease Drug Pipeline Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Batten Disease Drug Pipeline by Regions
4.1 Batten Disease Drug Pipeline Market Size by Regions (2018-2023)
4.2 Americas Batten Disease Drug Pipeline Market Size Growth (2018-2023)
4.3 APAC Batten Disease Drug Pipeline Market Size Growth (2018-2023)
4.4 Europe Batten Disease Drug Pipeline Market Size Growth (2018-2023)
4.5 Middle East & Africa Batten Disease Drug Pipeline Market Size Growth (2018-2023)
5 Americas
5.1 Americas Batten Disease Drug Pipeline Market Size by Country (2018-2023)
5.2 Americas Batten Disease Drug Pipeline Market Size by Type (2018-2023)
5.3 Americas Batten Disease Drug Pipeline Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Batten Disease Drug Pipeline Market Size by Region (2018-2023)
6.2 APAC Batten Disease Drug Pipeline Market Size by Type (2018-2023)
6.3 APAC Batten Disease Drug Pipeline Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Batten Disease Drug Pipeline by Country (2018-2023)
7.2 Europe Batten Disease Drug Pipeline Market Size by Type (2018-2023)
7.3 Europe Batten Disease Drug Pipeline Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Batten Disease Drug Pipeline by Region (2018-2023)
8.2 Middle East & Africa Batten Disease Drug Pipeline Market Size by Type (2018-2023)
8.3 Middle East & Africa Batten Disease Drug Pipeline Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Batten Disease Drug Pipeline Market Forecast
10.1 Global Batten Disease Drug Pipeline Forecast by Regions (2024-2029)
10.1.1 Global Batten Disease Drug Pipeline Forecast by Regions (2024-2029)
10.1.2 Americas Batten Disease Drug Pipeline Forecast
10.1.3 APAC Batten Disease Drug Pipeline Forecast
10.1.4 Europe Batten Disease Drug Pipeline Forecast
10.1.5 Middle East & Africa Batten Disease Drug Pipeline Forecast
10.2 Americas Batten Disease Drug Pipeline Forecast by Country (2024-2029)
10.2.1 United States Batten Disease Drug Pipeline Market Forecast
10.2.2 Canada Batten Disease Drug Pipeline Market Forecast
10.2.3 Mexico Batten Disease Drug Pipeline Market Forecast
10.2.4 Brazil Batten Disease Drug Pipeline Market Forecast
10.3 APAC Batten Disease Drug Pipeline Forecast by Region (2024-2029)
10.3.1 China Batten Disease Drug Pipeline Market Forecast
10.3.2 Japan Batten Disease Drug Pipeline Market Forecast
10.3.3 Korea Batten Disease Drug Pipeline Market Forecast
10.3.4 Southeast Asia Batten Disease Drug Pipeline Market Forecast
10.3.5 India Batten Disease Drug Pipeline Market Forecast
10.3.6 Australia Batten Disease Drug Pipeline Market Forecast
10.4 Europe Batten Disease Drug Pipeline Forecast by Country (2024-2029)
10.4.1 Germany Batten Disease Drug Pipeline Market Forecast
10.4.2 France Batten Disease Drug Pipeline Market Forecast
10.4.3 UK Batten Disease Drug Pipeline Market Forecast
10.4.4 Italy Batten Disease Drug Pipeline Market Forecast
10.4.5 Russia Batten Disease Drug Pipeline Market Forecast
10.5 Middle East & Africa Batten Disease Drug Pipeline Forecast by Region (2024-2029)
10.5.1 Egypt Batten Disease Drug Pipeline Market Forecast
10.5.2 South Africa Batten Disease Drug Pipeline Market Forecast
10.5.3 Israel Batten Disease Drug Pipeline Market Forecast
10.5.4 Turkey Batten Disease Drug Pipeline Market Forecast
10.5.5 GCC Countries Batten Disease Drug Pipeline Market Forecast
10.6 Global Batten Disease Drug Pipeline Forecast by Type (2024-2029)
10.7 Global Batten Disease Drug Pipeline Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 Abeona Therapeutics Inc
11.1.1 Abeona Therapeutics Inc Company Information
11.1.2 Abeona Therapeutics Inc Batten Disease Drug Pipeline Product Offered
11.1.3 Abeona Therapeutics Inc Batten Disease Drug Pipeline Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Abeona Therapeutics Inc Main Business Overview
11.1.5 Abeona Therapeutics Inc Latest Developments
11.2 Amicus Therapeutics
11.2.1 Amicus Therapeutics Company Information
11.2.2 Amicus Therapeutics Batten Disease Drug Pipeline Product Offered
11.2.3 Amicus Therapeutics Batten Disease Drug Pipeline Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Amicus Therapeutics Main Business Overview
11.2.5 Amicus Therapeutics Latest Developments
11.3 Blue Turtle Bio Technologies Inc
11.3.1 Blue Turtle Bio Technologies Inc Company Information
11.3.2 Blue Turtle Bio Technologies Inc Batten Disease Drug Pipeline Product Offered
11.3.3 Blue Turtle Bio Technologies Inc Batten Disease Drug Pipeline Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Blue Turtle Bio Technologies Inc Main Business Overview
11.3.5 Blue Turtle Bio Technologies Inc Latest Developments
11.4 Circumvent Pharmaceuticals Inc
11.4.1 Circumvent Pharmaceuticals Inc Company Information
11.4.2 Circumvent Pharmaceuticals Inc Batten Disease Drug Pipeline Product Offered
11.4.3 Circumvent Pharmaceuticals Inc Batten Disease Drug Pipeline Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Circumvent Pharmaceuticals Inc Main Business Overview
11.4.5 Circumvent Pharmaceuticals Inc Latest Developments
11.5 Collaborations Pharmaceuticals Inc
11.5.1 Collaborations Pharmaceuticals Inc Company Information
11.5.2 Collaborations Pharmaceuticals Inc Batten Disease Drug Pipeline Product Offered
11.5.3 Collaborations Pharmaceuticals Inc Batten Disease Drug Pipeline Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Collaborations Pharmaceuticals Inc Main Business Overview
11.5.5 Collaborations Pharmaceuticals Inc Latest Developments
11.6 Exicure Inc
11.6.1 Exicure Inc Company Information
11.6.2 Exicure Inc Batten Disease Drug Pipeline Product Offered
11.6.3 Exicure Inc Batten Disease Drug Pipeline Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Exicure Inc Main Business Overview
11.6.5 Exicure Inc Latest Developments
11.7 Polaryx Therapeutics Inc
11.7.1 Polaryx Therapeutics Inc Company Information
11.7.2 Polaryx Therapeutics Inc Batten Disease Drug Pipeline Product Offered
11.7.3 Polaryx Therapeutics Inc Batten Disease Drug Pipeline Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Polaryx Therapeutics Inc Main Business Overview
11.7.5 Polaryx Therapeutics Inc Latest Developments
11.8 RegenxBio Inc
11.8.1 RegenxBio Inc Company Information
11.8.2 RegenxBio Inc Batten Disease Drug Pipeline Product Offered
11.8.3 RegenxBio Inc Batten Disease Drug Pipeline Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 RegenxBio Inc Main Business Overview
11.8.5 RegenxBio Inc Latest Developments
11.9 Retrotope Inc
11.9.1 Retrotope Inc Company Information
11.9.2 Retrotope Inc Batten Disease Drug Pipeline Product Offered
11.9.3 Retrotope Inc Batten Disease Drug Pipeline Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Retrotope Inc Main Business Overview
11.9.5 Retrotope Inc Latest Developments
12 Research Findings and Conclusion